No Cover Image

Journal article 392 views 125 downloads

Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Esteban Jódar, Marie Michelsen, William Polonsky, Rosangela Réa, Anna Sandberg, Tina Vilsbøll, Mark Warren, Signe Harring, Uwe Ziegler, Steve Bain Orcid Logo

Diabetes, Obesity and Metabolism

Swansea University Author: Steve Bain Orcid Logo

  • 54313VOR.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).

    Download (1.08MB)

Check full text

DOI (Published version): 10.1111/dom.14039

Published in: Diabetes, Obesity and Metabolism
ISSN: 1462-8902 1463-1326
Published: Wiley 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa54313
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2020-05-26T19:08:07Z
last_indexed 2023-01-11T14:32:18Z
id cronfa54313
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T18:46:38.1674795</datestamp><bib-version>v2</bib-version><id>54313</id><entry>2020-05-26</entry><title>Semaglutide improves health&#x2010;related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-05-26</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>Diabetes, Obesity and Metabolism</journal><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1462-8902</issnPrint><issnElectronic>1463-1326</issnElectronic><keywords>cardiovascular disease, GLP-1 analogue, hypoglycaemia, incretin therapy, type 2 diabetes,weight control</keywords><publishedDay>27</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-04-27</publishedDate><doi>10.1111/dom.14039</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T18:46:38.1674795</lastEdited><Created>2020-05-26T14:46:57.1998475</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Esteban</firstname><surname>J&#xF3;dar</surname><order>1</order></author><author><firstname>Marie</firstname><surname>Michelsen</surname><order>2</order></author><author><firstname>William</firstname><surname>Polonsky</surname><order>3</order></author><author><firstname>Rosangela</firstname><surname>R&#xE9;a</surname><order>4</order></author><author><firstname>Anna</firstname><surname>Sandberg</surname><order>5</order></author><author><firstname>Tina</firstname><surname>Vilsb&#xF8;ll</surname><order>6</order></author><author><firstname>Mark</firstname><surname>Warren</surname><order>7</order></author><author><firstname>Signe</firstname><surname>Harring</surname><order>8</order></author><author><firstname>Uwe</firstname><surname>Ziegler</surname><order>9</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>10</order></author></authors><documents><document><filename>54313__17521__c4d84b994aef4a59a538ada19d7158e8.pdf</filename><originalFilename>54313VOR.pdf</originalFilename><uploaded>2020-06-18T10:09:08.8822732</uploaded><type>Output</type><contentLength>1130633</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Released under the terms of a Creative Commons Attribution&#x2010;NonCommercial License (CC-BY-NC).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T18:46:38.1674795 v2 54313 2020-05-26 Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6) 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2020-05-26 BMS Journal Article Diabetes, Obesity and Metabolism Wiley 1462-8902 1463-1326 cardiovascular disease, GLP-1 analogue, hypoglycaemia, incretin therapy, type 2 diabetes,weight control 27 4 2020 2020-04-27 10.1111/dom.14039 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-12-02T18:46:38.1674795 2020-05-26T14:46:57.1998475 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Esteban Jódar 1 Marie Michelsen 2 William Polonsky 3 Rosangela Réa 4 Anna Sandberg 5 Tina Vilsbøll 6 Mark Warren 7 Signe Harring 8 Uwe Ziegler 9 Steve Bain 0000-0001-8519-4964 10 54313__17521__c4d84b994aef4a59a538ada19d7158e8.pdf 54313VOR.pdf 2020-06-18T10:09:08.8822732 Output 1130633 application/pdf Version of Record true Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC). true eng http://creativecommons.org/licenses/by-nc/4.0/
title Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
spellingShingle Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
Steve Bain
title_short Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_full Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_fullStr Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_full_unstemmed Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_sort Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Esteban Jódar
Marie Michelsen
William Polonsky
Rosangela Réa
Anna Sandberg
Tina Vilsbøll
Mark Warren
Signe Harring
Uwe Ziegler
Steve Bain
format Journal article
container_title Diabetes, Obesity and Metabolism
publishDate 2020
institution Swansea University
issn 1462-8902
1463-1326
doi_str_mv 10.1111/dom.14039
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
published_date 2020-04-27T04:07:46Z
_version_ 1763753556042579968
score 10.993443